FDA 522 Zimmer Metal-on-Metal Hip Explant Study

The Food and Drug Administration (FDA), pursuant to Section 522 of the Food, Drug and Cosmetic Act, 21 USC § 3601, has ordered medical device manufacturers, including Zimmer, Inc. (“Zimmer”), to conduct post market surveillance studies of their metal-on-metal hip implants.

Part of the post-market surveillance includes the study of explanted retrievals when made available after medically necessary surgical intervention. Below you will find copies of all the pertinent letters and forms for this activity.

Zimmer Communications

Patient Consent/Decline

This material is intended for health care professionals.  Distribution to any other recipient is prohibited.  For indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert or contact your local representative; visit www.zimmerbiomet.com for additional product information.
All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.  
Not all products shown herein are available in all regions; check for product country clearances and reference product-specific instructions for use.
Talk to your surgeon about whether joint replacement or another treatment is right for you and the risks of the procedure, including the risk of implant wear, loosening or failure, and pain, swelling and infection. Zimmer Biomet does not practice medicine; only a surgeon can answer your questions regarding your individual symptoms, diagnosis and treatment.